NASDAQ$BIIB
Biogen Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Biogen reported first quarter results and reaffirmed full year guidance.
Biogen's first quarter 2023 revenue reached $2,463 million, with a GAAP diluted EPS of $2.67 and a Non-GAAP diluted EPS of $3.40. The company is focused on potential launches in Alzheimer’s disease and ALS, while also prioritizing R&D and optimizing its operating model.
- Continued progress on three potential launches in 2023.
- LEQEMBI FDA Accelerated Approval received; traditional approval filing submitted.
- Zuranolone New Drug Application accepted in the U.S. with Priority Review.
- Advisory Committee agreed on potential clinical benefit of tofersen for SOD1-ALS.
Headline financials
Revenue & EPS history
Biogen · Revenue · Quarterly
$2.46B
Forward guidance
Biogen reaffirms its full year 2023 guidance, expecting a mid-single digit percentage decline in total revenue versus 2022 and Non-GAAP diluted EPS between $15.00 and $16.00.
Tailwinds
- Guidance assumes foreign exchange rates as of March 31, 2023, will remain in effect for the remainder of the year, net of hedging activities.
- Reaffirms full year 2023 revenue guidance.
- Reaffirms full year 2023 Non-GAAP diluted EPS guidance.
- Focus on execution of three potential launches in 2023.
- Diligent in prioritizing R&D pipeline.
Headwinds
- Guidance does not include any impact from potential acquisitions or large business development transactions or pending and future litigation, as all are hard to predict.
- Guidance does not include any impact of potential tax or healthcare reform.
- Potential acquisitions or large business development transactions could cause actual results to vary from this financial guidance.
- Pending and future litigation could cause actual results to vary from this financial guidance.
- Potential tax or healthcare reform could cause actual results to vary from this financial guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+0.3%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+0.9%
Avg return
30 days after
48%
34 / 71 earnings
Positive
+24.7%
Q3 2019
Best reaction
-19.6%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.0% | +2.1% | +6.9% | |
| Q4 2025 | +8.5% | +3.2% | -0.3% | |
| Q3 2025 | +0.9% | +1.0% | +23.2% | |
| Q1 2025 | -0.1% | -3.5% | +7.2% | |
| Q4 2024 | -4.3% | -1.5% | +0.0% | |
| Q3 2024 | -5.2% | -5.4% | -12.4% | |
| Q2 2024 | -3.5% | -6.1% | -4.0% | |
| Q1 2024 | +4.8% | +11.6% | +12.7% | |
| Q4 2023 | -9.8% | -10.5% | -10.3% | |
| Q3 2023 | -8.5% | -9.4% | -2.6% | |
| Q2 2023 | -4.2% | -4.2% | -5.3% | |
| Q1 2023 | -1.7% | +3.8% | +1.4% | |
| Q4 2022 | -6.1% | -3.7% | -9.0% | |
| Q3 2022 | +2.1% | +3.5% | +10.5% | |
| Q2 2022 | -2.8% | -5.8% | -2.8% | |
| Q1 2022 | +1.3% | -6.6% | -4.2% | |
| Q4 2021 | -1.5% | -1.1% | -6.9% | |
| Q3 2021 | +0.8% | +0.7% | -4.1% | |
| Q2 2021 | +0.8% | +3.4% | +5.8% | |
| Q1 2021 | -2.7% | -0.9% | +4.9% | |
| Q4 2020 | -3.7% | -3.2% | -2.5% | |
| Q3 2020 | -0.1% | -3.9% | -8.6% | |
| Q2 2020 | -0.6% | +2.1% | -1.1% | |
| Q1 2020 | -11.2% | -7.8% | -7.4% | |
| Q4 2019 | -4.8% | +0.3% | +9.2% | |
| Q3 2019 | +24.7% | +28.9% | +29.1% | |
| Q2 2019 | +3.8% | +2.5% | -0.2% | |
| Q1 2019 | -0.1% | -0.4% | -1.4% | |
| Q4 2018 | -0.7% | +0.3% | -0.6% | |
| Q3 2018 | -4.3% | -4.9% | +0.0% | |
| Q2 2018 | +7.2% | -5.0% | -4.5% | |
| Q1 2018 | +3.9% | +6.7% | +9.7% | |
| Q4 2017 | +6.2% | +1.8% | -15.5% | |
| Q3 2017 | -4.2% | -6.3% | -5.7% | |
| Q2 2017 | +3.8% | +1.0% | +0.3% | |
| Q1 2017 | +1.1% | -2.0% | -8.6% | |
| Q4 2016 | +1.8% | +1.5% | +4.4% | |
| Q3 2016 | +1.7% | -2.0% | +6.7% | |
| Q2 2016 | +9.7% | +9.4% | +20.7% | |
| Q1 2016 | +6.3% | — | — | |
| Q4 2015 | +2.3% | — | — | |
| Q3 2015 | +4.1% | — | — | |
| Q2 2015 | -19.6% | — | — | |
| Q1 2015 | -9.5% | — | — | |
| Q4 2014 | +10.8% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +4.1% | — | — | |
| Q3 2013 | +0.8% | — | — | |
| Q2 2013 | -1.5% | — | — | |
| Q1 2013 | +3.6% | — | — | |
| Q4 2012 | +5.3% | — | — | |
| Q3 2012 | -2.2% | — | — | |
| Q2 2012 | +3.0% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | +0.7% | — | — | |
| Q3 2011 | -1.2% | — | — | |
| Q2 2011 | -2.1% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q4 2010 | -0.5% | — | — | |
| Q3 2010 | +4.3% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q1 2009 | -3.8% | — | — | |
| Q1 2010 | -0.3% | — | — | |
| Q4 2007 | +2.9% | — | — | |
| Q3 2009 | -1.7% | — | — | |
| Q3 2008 | -1.7% | — | — | |
| Q4 2008 | -0.4% | — | — | |
| Q2 2009 | -0.4% | — | — | |
| Q2 2008 | -0.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro